Overall Survival Prediction and Usefulness of Second-Line Chemotherapy in Advanced Pancreatic Adenocarcinoma
Published 2017 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Overall Survival Prediction and Usefulness of Second-Line Chemotherapy in Advanced Pancreatic Adenocarcinoma
Authors
Keywords
-
Journal
JNCI-Journal of the National Cancer Institute
Volume 109, Issue 10, Pages -
Publisher
Oxford University Press (OUP)
Online
2017-02-23
DOI
10.1093/jnci/djx037
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Second-line therapy after nab-paclitaxel plus gemcitabine or after gemcitabine for patients with metastatic pancreatic cancer
- (2016) E Gabriela Chiorean et al. BRITISH JOURNAL OF CANCER
- Prognostic nomogram and score to predict overall survival in locally advanced untreated pancreatic cancer (PROLAP)
- (2016) Dewi Vernerey et al. BRITISH JOURNAL OF CANCER
- Cancer statistics, 2016
- (2016) Rebecca L. Siegel et al. CA-A CANCER JOURNAL FOR CLINICIANS
- Prognostic value of health-related quality of life for overall survival in elderly non-small-cell lung cancer patients
- (2016) Frédéric Fiteni et al. EUROPEAN JOURNAL OF CANCER
- Metastatic Pancreatic Cancer: American Society of Clinical Oncology Clinical Practice Guideline
- (2016) Davendra P.S. Sohal et al. JOURNAL OF CLINICAL ONCOLOGY
- Nanoliposomal irinotecan with fluorouracil and folinic acid in metastatic pancreatic cancer after previous gemcitabine-based therapy (NAPOLI-1): a global, randomised, open-label, phase 3 trial
- (2016) Andrea Wang-Gillam et al. LANCET
- Second-Line Treatment in Pancreatic Cancer Patients
- (2016) Marianne Sinn et al. PANCREAS
- Prognostic Scoring Index for Patients with Metastatic Pancreatic Adenocarcinoma
- (2016) Hyung Soon Park et al. Cancer Research and Treatment
- Prognostic value of health-related quality of life for death risk stratification in patients with unresectable glioblastoma
- (2016) Brice Paquette et al. Cancer Medicine
- Transparent Reporting of a multivariable prediction model for Individual Prognosis Or Diagnosis (TRIPOD): Explanation and Elaboration
- (2015) Karel G.M. Moons et al. ANNALS OF INTERNAL MEDICINE
- Cancer of the pancreas: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up
- (2015) M. Ducreux et al. ANNALS OF ONCOLOGY
- Transparent reporting of a multivariable prediction model for individual prognosis or diagnosis (TRIPOD): The TRIPOD statement
- (2015) G S Collins et al. BRITISH JOURNAL OF CANCER
- Nab-paclitaxel plus gemcitabine for metastatic pancreatic adenocarcinoma after Folfirinox failure: an AGEO prospective multicentre cohort
- (2015) Alix Portal et al. BRITISH JOURNAL OF CANCER
- Decision Curve Analysis
- (2015) Mark Fitzgerald et al. JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION
- Randomized, Double-Blind, Phase II Study of Ruxolitinib or Placebo in Combination With Capecitabine in Patients With Metastatic Pancreatic Cancer for Whom Therapy With Gemcitabine Has Failed
- (2015) Herbert I. Hurwitz et al. JOURNAL OF CLINICAL ONCOLOGY
- Nomograms in oncology: more than meets the eye
- (2015) Vinod P Balachandran et al. LANCET ONCOLOGY
- Impact of Smoking on Pancreatic Cancer Patients Receiving Current Chemotherapy
- (2015) Chihiro Kawaguchi et al. PANCREAS
- State of the art and future directions of pancreatic ductal adenocarcinoma therapy
- (2015) Cindy Neuzillet et al. PHARMACOLOGY & THERAPEUTICS
- Prognostic value of health-related quality of life in patients with metastatic pancreatic adenocarcinoma: a random forest methodology
- (2015) Momar Diouf et al. QUALITY OF LIFE RESEARCH
- Pancreatic Adenocarcinoma
- (2015) David P. Ryan et al. NEW ENGLAND JOURNAL OF MEDICINE
- Projecting Cancer Incidence and Deaths to 2030: The Unexpected Burden of Thyroid, Liver, and Pancreas Cancers in the United States
- (2014) L. Rahib et al. CANCER RESEARCH
- Could baseline health-related quality of life (QoL) predict overall survival in metastatic colorectal cancer? The results of the GERCOR OPTIMOX 1 study
- (2014) Momar Diouf et al. Health and Quality of Life Outcomes
- Second-Line Oxaliplatin, Folinic Acid, and Fluorouracil Versus Folinic Acid and Fluorouracil Alone for Gemcitabine-Refractory Pancreatic Cancer: Outcomes From the CONKO-003 Trial
- (2014) Helmut Oettle et al. JOURNAL OF CLINICAL ONCOLOGY
- Beyond first-line chemotherapy for advanced pancreatic cancer: An expanding array of therapeutic options?
- (2014) Evan J Walker WORLD JOURNAL OF GASTROENTEROLOGY
- Second-line treatment in advanced pancreatic cancer: a comprehensive analysis of published clinical trials
- (2013) O. E. Rahma et al. ANNALS OF ONCOLOGY
- Increased Survival in Pancreatic Cancer with nab-Paclitaxel plus Gemcitabine
- (2013) Daniel D. Von Hoff et al. NEW ENGLAND JOURNAL OF MEDICINE
- Impact of FOLFIRINOX Compared With Gemcitabine on Quality of Life in Patients With Metastatic Pancreatic Cancer: Results From the PRODIGE 4/ACCORD 11 Randomized Trial
- (2012) Sophie Gourgou-Bourgade et al. JOURNAL OF CLINICAL ONCOLOGY
- Cigarette smoking and pancreatic cancer: an analysis from the International Pancreatic Cancer Case-Control Consortium (Panc4)
- (2011) C. Bosetti et al. ANNALS OF ONCOLOGY
- A Prognostic Model to Identify Patients with Advanced Pancreas Adenocarcinoma Who Could Benefit from Second-line Chemotherapy
- (2011) Seung Tae Kim et al. CLINICAL ONCOLOGY
- Best supportive care (BSC) versus oxaliplatin, folinic acid and 5-fluorouracil (OFF) plus BSC in patients for second-line advanced pancreatic cancer: A phase III-study from the German CONKO-study group
- (2011) Uwe Pelzer et al. EUROPEAN JOURNAL OF CANCER
- FOLFIRINOX versus Gemcitabine for Metastatic Pancreatic Cancer
- (2011) Thierry Conroy et al. NEW ENGLAND JOURNAL OF MEDICINE
Find Funding. Review Successful Grants.
Explore over 25,000 new funding opportunities and over 6,000,000 successful grants.
ExploreCreate your own webinar
Interested in hosting your own webinar? Check the schedule and propose your idea to the Peeref Content Team.
Create Now